Sudan Virus, one of the viruses that cause Ebola disease, has seen seven outbreaks since it was first discovered in the 1970s, four of which were in Uganda, and three in Sudan.

Vaccine trials on Sudan Ebola strain to start in weeks - WHO chief. By Elias Biryabarema. October 12, 2022 3:18 PM UTC Updated October 12, 2022 Item 1 of 2 Dr Tedros Adhanom ...

South Sudan received 2,160 doses of the yet-to-be-licensed Ebola vaccine, which was developed by American pharmaceutical company Merck and protects against the Zaire strain of the virus that's ...

But that doesn't mean Sudan Ebola virus isn't very deadly. According to the WHO, earlier outbreaks have seen mortality rates ranging from 41 to 100%.

The World Health Organization director for Africa said Uganda has started a clinical trial of a vaccine against the Sudan strain of Ebola, for which there is currently no approved vaccine.

A Sudan Ebola vaccine, provided by the International AIDS Vaccine Initiative (IAVI), is being investigated in a Uganda ...

Given the current outbreak of Ebola Sudan in Uganda, this work is now even more important," said Assistant Secretary for Preparedness and Response Dawn O'Connell in a statement.

Ebola Zaire is the most common cause of outbreaks, followed by Ebola Sudan. But there are long stretches between outbreaks of the latter, making it difficult to test drugs or vaccines for this ...

The 2022 health crisis was Uganda’s seventh outbreak of Ebola – a highly infectious hemorrhagic disease – and its fifth of ...

UN suspends Ebola screening after 3 aid workers killed in South Sudan. Two other aid workers were wounded, and another was abducted along with a child.

KAMPALA, Uganda — Ugandan authorities on Monday began a clinical trial of a vaccine against the Sudan strain of Ebola that has killed one person in the outbreak declared last week.

JUBA, South Sudan (AP) — With the deadly Ebola outbreak in Congo now an international emergency , neighboring South Sudan and its war-weakened health system is a major concern, especially after ...